PMID- 35045564
OWN - NLM
STAT- MEDLINE
DCOM- 20220418
LR  - 20230916
IS  - 1473-5687 (Electronic)
IS  - 0954-691X (Print)
IS  - 0954-691X (Linking)
VI  - 34
IP  - 5
DP  - 2022 May 1
TI  - Randomized control trial on the efficacy of Limosilactobacillus reuteri ATCC PTA 
      4659 in reducing inflammatory markers in acute uncomplicated diverticulitis.
PG  - 496-502
LID - 10.1097/MEG.0000000000002342 [doi]
AB  - INTRODUCTION: Recent guidelines suggest treating acute uncomplicated 
      diverticulitis (AUD) without antibiotics. We tested the efficacy of 
      Limosilactobacillus reuteri ATCC PTA 4659 in AUD. Primary outcome was the 
      reduction of abdominal pain and inflammatory markers [C-reactive protein (C-RP) 
      and calprotectin]. Secondary outcome was the reduction of hours of 
      hospitalization. PATIENTS AND METHODS: A double-blind, randomized controlled 
      trial was conducted in 119 patients with AUD. The probiotic group (61 patients) 
      was treated with fluids, bowel rest and L. reuteri/b.i.d. for 10 days. The 
      placebo group (58 patients) was treated with the same therapy and placebo/b.i.d. 
      for 10 days. All patients completed a daily visual analogue scale (VAS) for 
      abdominal pain. RESULTS: Both groups showed a mean VAS score of 7 at enrolment 
      and a reduction of 4 points after 3 days. C-RP value, after 72 h, decreased by 
      58.8% in the probiotic group and by only 40% in the placebo group (P < 0.05). 
      Calprotectin levels, after 72 h, decreased by 17% in the probiotic group and by 
      only 10.6% in the control group (P < 0.05). In the probiotic group, the 
      hospitalization was done for 75.5 h compared to 83.5 in the placebo group. 
      CONCLUSIONS: The supplementation with L. reuteri 4659 together with bowel rest 
      and fluids significantly reduced both blood and faecal inflammatory markers 
      compared to the placebo group.
CI  - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Ojetti, Veronica
AU  - Ojetti V
AD  - Emergency Department - Fondazione Policlinico Universitario A. Gemelli, IRCCS, 
      Roma.
AD  - Emergency Department - Universita Cattolica del Sacro Cuore, Roma.
FAU - Saviano, Angela
AU  - Saviano A
AD  - Emergency Department - Universita Cattolica del Sacro Cuore, Roma.
FAU - Brigida, Mattia
AU  - Brigida M
AD  - Emergency Department - Universita Cattolica del Sacro Cuore, Roma.
FAU - Petruzziello, Carmine
AU  - Petruzziello C
AD  - Ospedale San Carlo di Nancy GVM care and Research, Rome.
FAU - Caronna, Martina
AU  - Caronna M
AD  - Emergency Department - Universita Cattolica del Sacro Cuore, Roma.
FAU - Gayani, Gunawardena
AU  - Gayani G
AD  - Emergency Department - Universita Cattolica del Sacro Cuore, Roma.
FAU - Franceschi, Francesco
AU  - Franceschi F
AD  - Emergency Department - Fondazione Policlinico Universitario A. Gemelli, IRCCS, 
      Roma.
AD  - Emergency Department - Universita Cattolica del Sacro Cuore, Roma.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Eur J Gastroenterol Hepatol
JT  - European journal of gastroenterology & hepatology
JID - 9000874
RN  - 0 (Leukocyte L1 Antigen Complex)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Abdominal Pain/etiology
MH  - C-Reactive Protein/metabolism
MH  - *Diverticulitis/therapy
MH  - Double-Blind Method
MH  - Humans
MH  - *Limosilactobacillus reuteri/metabolism
MH  - Leukocyte L1 Antigen Complex
MH  - *Probiotics/adverse effects
MH  - Treatment Outcome
PMC - PMC9936969
COIS- There are no conflicts of interest.
EDAT- 2022/01/20 06:00
MHDA- 2022/04/19 06:00
PMCR- 2023/02/17
CRDT- 2022/01/19 20:16
PHST- 2022/01/20 06:00 [pubmed]
PHST- 2022/04/19 06:00 [medline]
PHST- 2022/01/19 20:16 [entrez]
PHST- 2023/02/17 00:00 [pmc-release]
AID - 00042737-202205000-00004 [pii]
AID - 10.1097/MEG.0000000000002342 [doi]
PST - ppublish
SO  - Eur J Gastroenterol Hepatol. 2022 May 1;34(5):496-502. doi: 
      10.1097/MEG.0000000000002342.